DENVER, Oct. 9, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Tuesday, October 29, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.
This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:
Tuesday, October 29, 2024
Starting at 5:00 p.m. EDT
Webcast can be accessed using this link
Dial in number: 877-918-6630
International dial in: 517-308-9042
When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the conference call will be able to access a replay via our website at investors.davita.com. There will be no telephone replay.
About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of June 30, 2024, DaVita served approximately 265,100 patients at 3,124 outpatient dialysis centers, of which 2,672 centers were located in the United States and 452 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
Contact Information
Investors:
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$121.35 |
| Daily Change: | 1.02 0.85 |
| Daily Volume: | 765,000 |
| Market Cap: | US$8.570B |
December 11, 2025 October 29, 2025 August 05, 2025 May 12, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load